KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Asset Writedowns and Impairment: 2010-2024

Historic Asset Writedowns and Impairment for Nektar Therapeutics (NKTR) over the last 2 years, with Jun 2024 value amounting to $8.3 million.

  • Nektar Therapeutics' Asset Writedowns and Impairment fell 37.16% to $8.3 million in Q2 2024 from the same period last year, while for Jun 2024 it was $30.9 million, marking a year-over-year decrease of 11.59%. This contributed to the annual value of $8.3 million for FY2024, which is 76.42% down from last year.
  • Per Nektar Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $8.3 million for Q2 2024, which was up 740.69% from -$1.3 million recorded in Q4 2023.
  • Nektar Therapeutics' 5-year Asset Writedowns and Impairment high stood at $57.3 million for Q2 2022, and its period low was -$1.3 million during Q4 2023.
  • Over the past 3 years, Nektar Therapeutics' median Asset Writedowns and Impairment value was $9.4 million (recorded in 2023), while the average stood at $13.7 million.
  • The largest annual percentage gain for Nektar Therapeutics' Asset Writedowns and Impairment in the last 5 years was 780.58% (2023), contrasted with its biggest fall of 117.96% (2023).
  • Quarterly analysis of 3 years shows Nektar Therapeutics' Asset Writedowns and Impairment stood at $7.2 million in 2022, then slumped by 117.96% to -$1.3 million in 2023, then tumbled by 37.16% to $8.3 million in 2024.
  • Its last three reported values are $8.3 million in Q2 2024, -$1.3 million for Q4 2023, and $10.6 million during Q3 2023.